Novartis Pharmaceuticals has reported positive results from the PIONEER-HF trial of entresto for the treatment of heart failure with reduced ejection fraction (HFrEF) patients who had been admitted for acute decompensation heart failure (ADHF) event.

The study investigated the safety, tolerability, and efficacy of in-hospital initiation of entrestoin in comparison with enalapril.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The primary objective of the trial was met when patients treated with entresto demonstrated a 29% reduction in time-averaged N-terminal pro-B-type natriuretic peptide (NT-proBNP) at weeks four and eight compared to patients treated with enalapril.

It was found that the superiority of entresto over enalapril was consistent in reducing NT-proBNP across the HFrEF patient groups who were stabilised following admission for ADHF. The numbers of serious adverse events were found to be similar in both groups.

“PIONEER-HF further confirmed the safety and benefit, as reflected in the reduction of an important biomarker, of in-hospital initiation of entresto treatment.”

Novartis’ pre-specified exploratory analysis showed that the composite endpoint of death, re-hospitalisation for heart failure, left ventricular assist device (LVAD) implantation or listing for cardiac transplant occurred in 9.3% of patients treated with entresto and 16.8% in the enalapril group.

Novartis Pharmaceuticals chief medical officer Shreeram Aradhye said: “PIONEER-HF further confirmed the safety and benefit, as reflected in the reduction of an important biomarker, of in-hospital initiation of entresto treatment in HFrEF patients stabilised following ADHF.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Together with data from the PARADIGM-HF study, which demonstrated the superior benefit of entresto compared to an ACEi on cardiovascular mortality and HF hospitalisations in ambulatory patients, there is now consistent evidence in the in-and-outpatient settings supporting the use of entresto.”

PIONEER-HF is a prospective, multi-centre, double-blind, controlled trial that enrolled 881 patients.

Patients were randomly assigned to received a twice-daily dose of entresto or enalapril.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact